Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Nov 21, 2014 4:42pm
414 Views
Post# 23153762

Pharma Discussions - Clarification

Pharma Discussions - Clarification
FYI:  I asked a couple of questions of the company yesterday, to which I received answers today.  Here is what I found out (some of this information is repeat in the sense that it was reported before - but it's nice to get an updated status):

QUESTION "A":  In the last Webcast, the very last line in the presentation mentioned that business development, partnership and licensing discussions had "commenced."  What was meant by that statement?  My understanding is that such discussions have been ongoing for many years.  Thus, did something happen recently that caused such discussions to re-commence or be renewed?  What changed recently? 

ANSWER "A":  Without reading too much into the word ‘commenced’ on the final slide of the webcast presentation, it was/is meant to reflect that new discussions have commenced with new pharma. We are still in ongoing discussions with pharma whom we already have an established rapport.
 
QUESTION "B":   Are such discussions (as mentioned in question 8) still ongoing and in active mode? 

ANSWER "B":  Yes ongoing/active.

(Highlighting added by me)
Bullboard Posts